Literature DB >> 4048359

Naloxone reduces food intake in humans.

M R Cohen, R M Cohen, D Pickar, D L Murphy.   

Abstract

Hypotheses generated from animal studies that the endogenous opioid system is an important modulator of food intake suggest that blockade of the system in humans should affect eating behavior. To assess this hypothesis, seven normal volunteers were given 2 mg/kg naloxone or placebo on separate days in a double-blind, random but balanced cross-over experimental design. Compared to placebo, naloxone was found to reduce significantly total food intake from preselected prepared trays served 2.75 and 7.75 hours after drug administration (p less than 0.02). The reduction was considerable (28%), and although the magnitude varied greatly among individuals, reduction occurred in each. This reduced food intake was not accompanied by a demonstrable alteration of the volunteers' perceptions of their hunger. Further cautious experimental investigation of naloxone's effects during long-term administration and in patients with eating disorders is warranted in light of its apparent effect of reducing food intake in humans while not decreasing their satiety.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4048359     DOI: 10.1097/00006842-198503000-00004

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  8 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Effects of nalmefene on feeding in humans. Dissociation of hunger and palatability.

Authors:  M R Yeomans; P Wright; H A Macleod; J A Critchley
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Pharmacotherapies for Overeating and Obesity.

Authors:  S Yarnell; M Oscar-Berman; Nm Avena; K Blum; Ms Gold
Journal:  J Genet Syndr Gene Ther       Date:  2013-04-01

4.  Naltrexone in primary hyperphagic obesity wity hypochondriacal disorder - a clinical study.

Authors:  R S Pandey; S C Arya; D K Subbakrishna
Journal:  Indian J Psychiatry       Date:  1999-04       Impact factor: 1.759

5.  Does naloxone reinstate secondary hyperalgesia in humans after resolution of a burn injury? A placebo-controlled, double-blind, randomized, cross-over study.

Authors:  Manuel P Pereira; Mads U Werner; Thomas K Ringsted; Michael C Rowbotham; Bradley K Taylor; Joergen B Dahl
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

6.  Effects of target-controlled infusion of high-dose naloxone on pain and hyperalgesia in a human thermal injury model: a study protocol: A randomized, double-blind, placebo-controlled, crossover trial with an enriched design.

Authors:  Anders D Springborg; Elisabeth K Jensen; Bradley K Taylor; Mads U Werner
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

7.  Effect of a high-dose target-controlled naloxone infusion on pain and hyperalgesia in patients following groin hernia repair: study protocol for a randomized controlled trial.

Authors:  M P Pereira; M U Werner; J B Dahl; Manuel Pedro Pereira; Mads Utke Werner; Joergen Berg Dahl
Journal:  Trials       Date:  2015-11-10       Impact factor: 2.279

8.  High-dose naloxone: Effects by late administration on pain and hyperalgesia following a human heat injury model. A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design.

Authors:  Anders Deichmann Springborg; Elisabeth Kjær Jensen; Mads Kreilgaard; Morten Aagaard Petersen; Theodoros Papathanasiou; Trine Meldgaard Lund; Bradley Kenneth Taylor; Mads Utke Werner
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.